The QualityStocks Daily Tuesday, November 27th, 2018

Today's Top 3 StockMarketWatch

StockMarketWatch (ASNS) +255.17%

NetworkNewsWire (ZNGY) +50.00%

TaglichBrothers (AIRI) +35.84%

The QualityStocks Daily Stock List

IntelGenx Technologies Corp. (IGXT)

Streetwise Reports, StockInvest, MarketWatch, Stockhouse, GuruFocus, YCharts, Wolf Street, Market Screener, last10k, InvestorsHub, Zacks, Morningstar, Wallet Investor, Real Investment Advice, and Equity Clock reported previously on IntelGenx Technologies Corp. (IGXT), and we also report on the Company, here at the QualityStocks Daily Newsletter.

IntelGenx Technologies Corp. is a leading oral drug delivery company based in Saint-Laurent, Quebec. It primarily concentrates on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. The Company’s state-of-the-art manufacturing facility, constructed for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, providing full service capabilities to its clients. IntelGenx Technologies lists on the OTC Markets Group’s OTCQX.

The VersaFilm™ and VetaFilm™ rapidly disintegrating thin polymeric film technologies improve drug performance. Moreover, they ease administration without the need for water. IntelGenx states that the VersaFilm™ and VetaFilm™ products have the potential to enhance bioavailability, hasten onset of action, decrease side effects and ease administration, therefore improving patients’ compliance and satisfaction.

IntelGenx Technologies’ highly skilled team provides extensive pharmaceuticals services to pharmaceutical partners. These services include research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Additionally, the Company’s VetaFilm™ consists of R&D services for veterinary oral film technology.

This past September, IntelGenx Technologies announced that it executed a non-binding Letter of Intent (LOI) with Tilray, Inc. (TLRY) to co-develop and commercialize oral film products infused with recreational and medical cannabis (cannabis-infused VersaFilm™), in expectation of amended cannabis regulations that would allow adult-use consumers to purchase edible products. Tilray is a global leader in cannabis research, cultivation, production and distribution.

This month, IntelGenx announced the execution of a definitive license, development, and supply agreement with Tilray, Inc. With the Agreement, the two companies will co-develop and commercialize oral film products infused with adult-use and medical cannabis (cannabis-infused VersaFilm™”). Under the Agreement, IntelGenx and Tilray will each fund 20 percent and 80 percent of the costs associated with the development of the cannabis-infused Versafilm™ products, respectively.

Today, IntelGenx announced that patient dosing has begun in the Phase 2a study of Montelukast VersaFilm™ in patients with mild to moderate Alzheimer’s Disease (AD). The True North Clinical Research site in Kentville, Nova Scotia is the first of eight research sites in Canada to enroll a patient and start dosing. The randomized, double-blind, placebo controlled Phase 2a proof of concept study will enroll about 70 subjects with mild to moderate AD.  The study will evaluate the safety, feasibility, tolerability, and efficacy of Montelukast buccal film following daily dosing for 26 weeks.

IntelGenx Technologies Corp. (IGXT), closed Tuesday's trading session at $0.62, even for the day, on 303,846 volume with 105 trades. The average volume for the last 3 months is 903,137 and the stock's 52-week low/high is $0.509/$1.83.

chart

Mexus Gold US (MXSG)

777 Stocks, SmallCapVoice, AllPennyStocks, Wall Street Reporter, FeedBlitz, OTC Picks, and Stock Guru reported earlier on Mexus Gold US (MXSG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 2009, Mexus Gold US is a mining company with holdings in Mexico. Its properties include the fully-owned Santa Elena Mine. This property is 54km NW of Caborca, Mexico. The Santa Elena mine sits in an area that is now undergoing mining by some of the largest mining companies in the world. Mexus Gold US is based in Carson City, Nevada.

The Company has drill results that show a high-grade, multi vein system throughout the Santa Elena mine. Its belief is that the Santa Elena mine has great potential and that a well- funded company will use the significant work already completed to further the project.

Mexus Gold US also owns rights to the Ures property located 80km N of Hermosillo, Mexico. The property contains 6900 acres. It has gold and copper on the property.

Mexus Gold US entered into a joint venture (JV) agreement with MarMar Holdings of Mexico at its Santa Elena mine. Under the 50/50 JV agreement, MarMar will operate the mine and carry all costs.

In January of this year, Mexus Gold US announced that it determined to acquire the concessions consisting of the San Felix Project. It entered into land surface use agreements and concession purchase agreements for different land parcels that expired under the prior owner’s failure to pay.

Additionally, Mexus announced the execution of an agreement with MarMar Holdings where each company owns a 50 percent share of the San Felix Project and designates MarMar Holdings as the operator of the daily production activities. The San Felix mine in Northern Mexico is a 26,000-plus acre property ready for production planned for 2018.

At the end of July 2017, Mexus Gold US President, Mr. Paul Thompson, and Mr. Marco Martinez, Chief Executive Officer (CEO) of MarMar Holdings, announced that there is a considerable amount of gold in the pregnant pond and on the heap leach pad that is being leached. Mexus geologist Mr. Cesar Lemas confirmed this.

Mr. Lemas’ personal assay lab showed the heap leaching solution, as of 2 weeks prior to the end of July, was producing 1.5grams AU and 18grams AG per m3. Moreover, he noted that the pregnant solution in the pond and heap should yield 145 oz. AU and 1700 oz. AG and the material being leached should yield 400 to 500 oz. AU and 3000 oz. AG with good recoveries. Mr. Lemas also noted at that time that new material being placed on Pad 2 was ranging 1.5 grams to 5 grams per ton AU.

In September, Mexus Gold US along with its JV partner, MarMar Holdings, announced that they produced gold in dore form due to its continuing operation at the Santa Elena mine.

Mr. Marco Martinez, CEO of MarMar Holdings, said that the recovery of gold will be ongoing now that the recovery system is in full working order. Mr. Martinez also stated that the objective is to bring production to 10,000 tons a day by year end.

Mexus Gold US (MXSG), closed Tuesday's trading session at $0.00813, up 1.12%, on 125,532 volume with 4 trades. The average volume for the last 3 months is 594,671 and the stock's 52-week low/high is $0.0051/$0.0704.

chart

Brightlane Corp. (BTLN)

MarketWatch, InvestorsHub, OTC Markets, Simply Wall St, Stockhouse, Barchart, 4-Traders, Morningstar, GuruFocus, Capital Cube, YCharts, InFrontAnalytics.com, Penny Stock Tweets, Market Exclusive, Marketwired, and TradingView reported on Brightlane Corp. (BTLN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Brightlane Corp. is a real estate operating company listed on the OTC Markets Group’s OTCQB. The Company provides an alternative pathway to home ownership by way of a right-to-purchase program after meeting certain criteria. Brightlane concentrates on acquiring, renovating, managing, and leasing low priced single-family homes mainly in the United States. The Company has its corporate office in Houston, Texas.

Brightlane provides opportunities in the affordable housing market including reasonable rents and leases. At present, the Company acquires single-family homes and portfolios of single-family homes. It pursues the acquisition of these kinds of homes via one-off purchases, the purchase of portfolios, as well as other methods of acquisition.

Brightlane’s criteria for acquisitions of single-family home portfolios are a portfolio size of 5 to 500 homes. The Company’s acquisition efforts are chiefly focused in the Southeast, Midwest, and Southwest regions of the U.S.

Brightlane is looking for growth in ancillary markets. It is enhancing its business plan to access higher value and higher profit market segments with synergistic effects to its business model.

The Company is working to expand its business model into different areas. These areas include multifamily, active adult living, and student housing. These areas also include build-to-rent in the affordable housing space, non-performing notes, as well as credit reporting. In addition, Brightlane will be executing a ground up construction platform of rental single and multifamily products.

Mr. Steve Helm, Brightlane’s President and Chief Executive Officer, stated, "Our market segment has evolved and Brightlane is responding accordingly.  With the current market evolution and market dynamics, we have now better aligned our acquisition strategies to most effectively utilize our $5 million credit facility and gain access to additional finance."

Furthermore, Mr. Helm stated, "One of our goals for 2018, which we believe can be accomplished this calendar year by adhering to our acquisition and corporate development initiatives, is to apply for admission to the NASDAQ Exchange."

Brightlane Corp. (BTLN), closed Tuesday's trading session at $0.085, down 5.56%, on 29,451 volume with 17 trades. The average volume for the last 3 months is 2,565 and the stock's 52-week low/high is $0.039/$1.69.

chart

Cerebain Biotech Corp. (CBBT)

Greenbackers, Viral Stocks, and Wall Street Mover reported on Cerebain Biotech Corp. (CBBT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Cerebain Biotech Corp. centers on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. A development-stage medical device enterprise, the Company formerly went by the name Discount Dental Materials, Inc. It changed its corporate name to Cerebain Biotech Corp. in June 2014.

Cerebain Biotech lists on the OTC Markets’ OTCQB. The Company is based in Costa Mesa, California.

Cerebain Biotech’s technology has allowed for the development of a medical device that can be implanted using a minimally invasive procedure. Upon implantation, through what will most likely be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.

Cerebain’s device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The Company’s patent-pending device is implanted in the omentum. The omentum is a protective layer of skin that protects the abdominal organs.

The design of the device is to stimulate the omentum in patients with Alzheimer’s disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s disease.

Cerebain Biotech will evaluate the effect of omental stimulation at different intervals and levels of stimulation to measure the device’s ability to slow, stop or reverse the progression of Alzheimer’s disease on patients. The Company’s novel device approach is supported by research and patient outcomes.

Cerebain Biotech has signed a Memorandum of Understanding (MOU) with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland. The purpose of the MOU is to commence testing of Cerebain’s Medical Device upon completion of development. Moreover, Cerebain has a manufacturing agreement with Sonos Medical, a medical device supplier.

At the beginning of March, Cerebain Biotech announced that its intention is to begin the search process to partner with a Contract Research Organization (CRO). The search comes as the Company prepares for clinical trials and the FDA application process in combination with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia. Furthermore, in March, Cerebain announced that its strategic partner, Sonos, added key personnel to its staff to facilitate the acceleration in development of the company’s medical device.

Cerebain Biotech Corp. (CBBT), closed Tuesday's trading session at $0.012, down 10.45%, on 315,000 volume with 14 trades. The average volume for the last 3 months is 326,200 and the stock's 52-week low/high is $0.0078/$0.3389.

chart

Destiny Media Technologies, Inc. (DSNY)

Wall Street Resources, Greenbackers, SmallCapVoice, Bullseyestox.com, Stockhouse, Blaque Capital Stocks, Breaking Bulls, and OTC Picks reported earlier on Destiny Media Technologies, Inc. (DSNY), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Destiny Media Technologies, Inc. provides services that enable content owners to securely display and distribute their audio and video content digitally via the internet. The Company’s two major services are Play MPE® and Clipstream®. It has granted patents for secure distribution and watermarking and a pending patent for cross platform PC and mobile streaming. Destiny Media Technologies is based in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB.

Play MPE® provides a standardized method to securely and cost effectively distribute pre-release music to radio stations and other music industry professionals, before it is ready for sale. Clipstream® is a video format that plays on any modern smart phone, tablet, internet, TV, or computer.

Destiny Media Technologies’ revenue and earnings growth has been propelled by the flagship Play MPE® system. The Play MPE® system is being embraced by the music industry as the standard for securely moving their pre-release music to radio stations and other recipients.

The Company has launched the next generation of the player used in the Clipstream® hosting and reporting service. This version contains the first approach in the industry utilizing the graphics processing unit of different devices to enhance the presentation of video within the browser using a browser technology named WebGL.

This new player can access resources unavailable to conventional technologies to upscale and enhance the video, improving the viewer experience. Initially designed for use in 3D rendering and game development, WebGL is a low-level 3D graphics API. It gives the Clipstream player access to strong additional resources for enhancing and presenting video. In addition, the new player includes several other fixes and performance enhancements. In late November, Destiny Media Technologies announced a change to its strategy. The Company said that effective immediately, Clipstream® business and technical development will be transitioned to maintenance and support only.

Presently, Destiny believes Clipstream® requires a considerable investment to continue to develop as a technology and as a business. As a result, the Company is reviewing strategic alternatives to capture the value of Clipstream®, its surrounding intellectual property (IP) and business, for its shareholders. Destiny Media Technologies will focus its resources on worldwide expansion of Play MPE®. The Play MPE® business currently produces 99 percent of Company revenues.

For the fiscal 2017 year ended August 31, 2017, Destiny Media Technologies’ revenue increased in all geographic territories for a total increase of roughly 3 percent to $3,445,014. This, combined with an 11 percent decrease in overall expenditures (to $3,170,580), resulted in eliminating the prior year’s net loss increasing to net income of $288,781.

Destiny Media Technologies, Inc. (DSNY), closed Tuesday's trading session at $0.19995, up 5.18%, on 565 volume with 3 trades. The average volume for the last 3 months is 46,173 and the stock's 52-week low/high is $0.0708/$0.28.

chart

ImageWare Systems, Inc. (IWSY)

Pennybuster, PennyStocks24, Wall Street Daily, Wall Street Resources, Greenbackers, Microcapmillionaires, and TaglichBrothers reported earlier on ImageWare Systems, Inc. (IWSY), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

ImageWare Systems, Inc. is a foremost developer of mobile and cloud-based multi-modal biometric identity management solutions, providing biometric, secure credential, and also law enforcement technologies. The Company’s biometric product line is scalable for worldwide deployment. Listed on the OTC Markets’ OTCQB, ImageWare Systems is headquartered in San Diego, California.

The Company’s biometric product line includes a multi-biometric engine. This engine is hardware and algorithm independent. This permits the enrolment and management of unlimited population sizes.

ImageWare’s identification products are used to manage and issue secure credentials. This includes national IDs, passports, driver's licenses, smart cards, and access control credentials. Its digital booking products provide law enforcement with integrated mug shot, fingerprint livescan, and investigative capabilities.

ImageWare has its GoCloudID.com. GoCloudID.com is a highly modular, SOA-based software platform. It delivers a first-rate capability to quickly develop and deploy highly secure, yet flexible standards based identity solutions.

The Company has its EPI Builder®. This provides the underpinning for a multi-modal biometric capture platform, which ensures device interoperability and support for centralized and distributed deployment models. Additionally, products include IWS Biometric Engine®. This is the first and only truly multi-modal, device-and algorithm-independent biometric software platform.

ImageWare Systems’ next-generation cloud identity management and authentication service is GoMobile Interactive™ (GMI). GMI is a cloud-based, multi-modal biometric mobile identity management solution. GMI is built upon the award-winning IWS Biometric Engine® (IWS BE), an SOA based server platform that enables advanced biometric data process and management with ESB connectivity.

ImageWare also has its GoVerifyID solution. GoVerifyID is its patented mobile biometric user authentication solution. The Company also has its GoVerifyID® Enterprise Suite. This is an innovative, multi-modal, multi-factor biometric authentication solution for the enterprise market.

GoVerifyID Enterprise Suite is an algorithm-agnostic solution. It is the first ever end-to-end biometric platform that seamlessly integrates with an enterprise's existing Microsoft infrastructure. This provides businesses a turnkey biometric solution for fast deployment in an afternoon or less.

ImageWare delivers inventive mobile capabilities to the wireless, financial services, and healthcare sectors. The pillphone® enabled by the Company’s GoMobile interactive push application platform, is Food and Drug Administration (FDA) cleared. It is the only mobile health management application secured by biometrics.

ImageWare Systems and Secure Channels, Inc. (SCI) are enhancing the world’s first Entertainment Security Operations Center with multi-factor biometric authentication. Secure Channels’ ESOC is the world’s first members’ only, closed end, centralized ecosystem for secure management of the entertainment industry’s chain-of-custody, content and intellectual property (IP). Therefore, this provides member clients with an automated architecture.

Coupled with ImageWare Systems’ GoVerifyID biometric identity management solution, it produces a seamless, secure method for authorizing, accessing, and administering valuable entertainment-related, work-in-process content. Secure Channels is a provider of unique security solutions designed to complement existing security investments.

GoVerifyID for IBM Security Access Manager (ISAM) is now available on the IBM Security App Exchange. GoVerifyID seamlessly integrates with IBM identity and access management technology. This is to provide a flexible, end-to-end, multi-modal, biometric security solution for all ISAM authentication processes.

ImageWare Systems, Inc. (IWSY), closed Tuesday's trading session at $0.73, up 15.36%, on 207,362 volume with 65 trades. The average volume for the last 3 months is 93,364 and the stock's 52-week low/high is $0.569/$2.24.

chart

Select Sands Corp. (SLSDF)

Investors Hangout, Wallet Investors, Penny Stock Hub, Wall Street Analyzer, Investopedia, Stock Gumshoe, Amigo Bulls, Tip Ranks, YCharts, Marketbeat, The Street, InvestorsHub, Stockhouse, TradingView, Zacks, Penny Stock Tweets, MarketWatch, Simply Wall St, Marketwired, Barchart, and OTC Markets reported on Select Sands Corp. (SLSDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Select Sands Corp. is an industrial Silica Product company listed on the OTCQX. The Company is developing its 100 percent owned, 520-acre Northern White, Tier-1, silica sands project located in the State of Arkansas. The Company previously went by the name La Ronge Gold Corp. It changed its name to Select Sands Corp. in November of 2014. The Company has its corporate office in Vancouver, British Columbia.

Silica Sand is quartz that over time, through the work of water and wind, has been broken down into tiny granules. Commercial Silica Sand is extensively used as a proppant by oil and gas companies. Furthermore, it is used in industrial processing. Whole Grain and Ground Silica products range in size, distributions, grain shapes, as well as chemical purity.

The Company’s Sandtown project has NI 43-101 (National Instrument 43-101) compliant Indicated Mineral Resources of 42.0MM tons (TetraTech Report; February 2016). Bell Farm has Inferred Mineral Resources of 49.6MM tons (Kleinfelder Report; April 2017). Both deposits are considered Northern White finer-grade sand deposits of 40-70 Mesh and 100 Mesh.

Select Sands has its Ozark Operations in Arkansas. This property is underlain by the Ordovician St. Peter sandstone formation, the source of premier industrial silica sand ‘Ottawa White’ frac sand. The Company entered into a binding Letter of Agreement for an option to acquire a 100 percent undivided right, title, and interest in the roughly 520-acre premium grade industrial silica sand/frac sand project in northeast Arkansas. The Arkansas project is strategically situated to supply sand to major U.S. oil & gas and Industrial & Specialty markets.

On October 18, 2018, Select Sands announced it placed certain employees at its Arkansas operations on temporary furlough until further notice.  Shipments and limited production continue. The Company is pursuing additional opportunities. This includes evaluating sand production and sand-related business opportunities in or near other basins.

Recently, Select Sands announced that it sold 80,000 tons of frac and industrial sands during Q3 2018. This is within its previous guidance of between 65,000 to 95,000 tons.

Zig Vitols, President and Chief Executive Officer of Select Sands, stated, “Sales continue through the quarter and are being supported with appropriate production. Much of the operations are running on single shift to insure optimum control of overhead.  As a result, the company has maintained its cash position similar to that reported at the end of Q2.  We believe the mid to long-term outlook for demand fundamentals will see a return of stronger shipments of the company’s products…”

Select Sands Corp. (SLSDF), closed Tuesday's trading session at $0.06, down 3.23%, on 115,804 volume with 21 trades. The average volume for the last 3 months is 239,698 and the stock's 52-week low/high is $0.058/$0.484.

chart

Bluestone Resources, Inc. (BBSRF)

Stock Orange, OTC Markets, MarketWatch, 4-Traders, Geology for Investors, Current Charts, Dividend Investor, Investors Hangout, Wallmine, Barchart, OtcStockWatch, and Penny Stock Hub reported earlier on Bluestone Resources, Inc. (BBSRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bluestone Resources, Inc. focuses on advancing its 100 percent owned Cerro Blanco Gold and Mita Geothermal Projects in Guatemala. Bluestone controls the required surface rights for the Mita Geothermal Project and the Cerro Blanco Project. The Cerro Blanco Project is a classic hot springs-related, low sulphidation gold-silver deposit. A mineral exploration and development company, Bluestone Resources is based in Vancouver, British Columbia.

The Cerro Blanco Project economics and updated mineral resource estimate for Cerro Blanco indicates a robust project with an expected nine-year mine life producing 952,000 ounces of gold and 3,141,000 ounces of silver. Initial capital expenditures estimated in the Preliminary Economic Assessment (PEA) to finance construction and commissioning is estimated at US$170.8 million with all in sustaining cash (AISC) estimated to be US$490 per ounce of gold produced.

The permitted Mita Geothermal Project is positioned contiguous to the Company’s Cerro Blanco Gold Project in Guatemala. It is in southeast Guatemala, about 160 kilometers by road from the capital, Guatemala City. The Mita geothermal resource was discovered in the late 1990’s during gold exploration in southeastern Guatemala.

The Cerro Blanco Gold Project is not dependent on the Mita Geothermal Project. Nonetheless, Company Management’s belief is that there are potential synergies between the two that enhance the economics of the Cerro Blanco Gold Project beyond what was outlined in the PEA.

This month, Bluestone Resources announced that it started a follow-up drill program on its Cerro Blanco Gold project. The drilling will center on converting Inferred Resources identified during the Feasibility Study (FS) infill drill program completed earlier IN 2018.

The updated resource estimate, released in a news release titled "Bluestone Increases Mineral Resources at the Cerro Blanco Gold Project" on September 10, 2018, identified 357,000 ounces or 1,373,342 tonnes grading 8.09 g/t Au in the inferred category. Furthermore, as the program advances it will also center on targeting extensions to veins, which are already in the mine plan but have not yet been totally tested.

Bluestone Resources, Inc. (BBSRF), closed Tuesday's trading session at $0.8924, up 4.99%, on 2,200 volume with 2 trades. The average volume for the last 3 months is 1,364 and the stock's 52-week low/high is $0.842/$1.35.

chart

Oncolix, Inc. (ONCX)

NetworkNewsWire, Stock News Now, Stockhouse, Penny Stock Hub, SmallCapVoice, Stockwatch, OTC Markets, Marketwired, The Street, Dividend Investor, Investopedia, Barchart, Stockopedia, and InvestorsHub reported earlier on Oncolix, Inc. (ONCX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Oncolix, Inc. is developing Prolanta™ for the treatment of ovarian, uterine, breast, and other cancers. Oncolix has a US FDA-cleared (Food and Drug Administration) IND to begin human testing of Prolanta™ in its first indication, the treatment of ovarian cancer. The Phase 1 clinical trial is now in progress. A clinical-stage biotechnology company, Oncolix has its corporate office in Houston, Texas. The Company lists on the OTCQB.

Oncolix believes Prolanta™ has the opportunity to treat a broad spectrum of human cancers. It states that there is substantial scientific evidence that human prolactin is associated with the growth of many cancers and also the development of resistance to common chemotherapies. Oncolix believes Prolanta™ will be effective against manifold cancers as a stand-alone therapy and also as part of combination therapy.

Prolanta™ is a prolactin receptor antagonist (or blocker). Prolanta™ has demonstrated efficacy in xenograft models by way of an innovative mechanism of action, autophagy. There is strong preclinical evidence Prolanta™ may be effective in breast, prostate, and other cancers, in addition to ovarian cancer.

Prolanta™ is undergoing evaluation in an open-label dose escalation Phase 1 clinical trial in patients with advanced ovarian cancer. Patients are divided into three dosing groups (cohorts). Each sequential cohort will evaluate a higher dose of Prolanta™. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, so far there have been no observed serious adverse events. In addition, there have been no dose-limiting toxicities. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer.

Oncolix announced in January 2018 that it sponsored additional research with MD Anderson Cancer Center. This research will evaluate Prolanta™ for the potential treatment of additional gynecological cancers, more specifically uterine cancer.

This past September, Oncolix announced that it entered into a non-binding Letter of Intent (LOI) for an exclusive worldwide license agreement from IGL Pharma, Inc., (IGLP) for a novel drug for the potential treatment of osteosarcoma, bone metastases and bone marrow ablation. The Proposal includes all uses for the drug, a radiopharmaceutical, Samarium-153 DOTMP (CycloSamTM).

Last month, Oncolix announced that it finalized its license agreement from IGL Pharma, Inc., (IGLP) for a novel, clinical stage drug for the treatment of osteosarcoma.

Mr. Michael Redman, Oncolix Chief Executive Officer, said, ''We are pleased to license this very exciting drug candidate. While our first target will be osteosarcoma, we plan to expand its use into bone metastases and bone marrow ablation, two additional large potential markets. Oncolix now has two promising oncology drugs in clinical stages.''

Oncolix, Inc. (ONCX), closed Tuesday's trading session at $0.01234, down 34.36%, on 53,100 volume with 5 trades. The average volume for the last 3 months is 111,005 and the stock's 52-week low/high is $0.0065/$0.0778.

chart

Fiore Gold Ltd. (FIOGF)

Investors Hangout, OTC Markets, TradingView, Investorx, Stockhouse, Stockwatch, Energy and Gold, Stock Orange, Barchart, Dividend Investor, WatchDog Stocks, and Pinnacle Digest reported earlier on Fiore Gold Ltd. (FIOGF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Fiore Gold Ltd. is a new America’s-focused gold producer and explorer listed on the OTCQB. The Company has the producing Pan Mine in Nevada. In addition, it has a group of exploration projects in Nevada, Washington and Chile. Fiore Gold has offices in Toronto, Ontario; Vancouver, British Columbia; and Englewood, Colorado.

The Company’s aim is to build a new mid-tier mining company in the world’s foremost mining jurisdictions. Fiore Gold’s initial objective is on becoming an 150,000-ounce/year gold producer. Concerning North American Projects, Fiore Gold’s assets include the producing Pan Mine near Eureka, Nevada. Assets additionally include the nearby Gold Rock exploration project. Fiore also controls the Golden Eagle advanced exploration project in Washington State.

The Pan Mine is a Carlin-style, sediment-hosted, gold-only deposit. Pan consists of three main zones of mineralization that has now been traced for more than 6,000 feet along the north-south Branham Fault. The 2017 Pan Mine Feasibility Study (FS) defines Proven and Probable reserves of 318,000 gold ounces at an average grade of 0.51 g/t gold (0.015 oz/ton). Fiore Gold earlier announced the commencement of exploration drilling at its Pan Mine, as part of a longer-term program intended to expand the resource and reserve base at Pan.

Regarding South American Properties, the Company has its Pampas El Peñon properties; the Cerro Tostado project; and the Rio Loa property. The Pampas El Peñon property consists of 13 mining claims totaling 3,400 hectares. It is roughly 130 kilometers southeast of Antofagasta, Chile.

The Cerro Tostado (South America) project consists of five concessions totaling about 1,500 ha situated in Region II approximately 125 km southeast of Antofagasta. The Rio Loa property is in the northern part of the prolific Maricunga gold belt. The 1,000 Ha Rio Loa property is around 25 km south of Salares Norte.

At the beginning of November, Fiore Gold provided results from eight exploration drill holes recently completed at its 100 percent-owned Gold Rock Property, White Pine County, Nevada. The holes targeted three of nine earlier-identified target areas north of the Gold Rock resource area that lies about 8 km southeast of the Company's Pan Mine. At present, Gold Rock hosts an Indicated Resource of 238,700 gold ounces (9.0 million tonnes at 0.82 g/t gold), and an Inferred Resource of 180,900 gold ounces (7.8 million tonnes at 0.72 g/t gold).

All eight holes intercepted the targeted Joanna Limestone unit. Six of the eight holes encountered anomalous gold mineralization, including 6.1 m at 0.67 g/t gold in hole GR18-04. The mineralization encountered was mainlty seen in the altered Joanna Limestone. However, mineralization also extended into carbonates in the base of the overlying Chainman Formation and in some cases the top of the underlying Pilot Shale.

Fiore Gold Ltd. (FIOGF), closed Tuesday's trading session at $0.265, up 0.38%, on 72,741 volume with 44 trades. The average volume for the last 3 months is 47,443 and the stock's 52-week low/high is $0.1569/$0.9537.

chart

Q BioMed, Inc. (QBIO)

StockPicksNYC, Stock News Now, and SeeThruEquityResearch reported previously on Q BioMed, Inc. (QBIO), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Q BioMed, Inc. is a biomedical acceleration and development company based in New York, New York. Its dedication is to licensing and acquiring biomedical assets across the healthcare spectrum. The Company formerly went by the name ISMO Tech Solutions, Inc. It changed its corporate name to Q BioMed, Inc. in July of 2015. Q BioMed lists on the OTC Markets’ OTCQB.

Q BioMed’s commitment is to provide these target assets the strategic resources, developmental support, and expansion capital they require to ensure they meet their developmental potential, enabling them to provide products to patients in need. The Company’s mission is to license and acquire ground-breaking life sciences assets from academia or small private companies.

Q BioMed is concentrating on clinical stage and innovative products where the technical, regulatory, as well as commercial risks have been decreased or major valuation inflections are pending. The Company has numerous assets across a broad spectrum of healthcare related products, companies, and sectors. These assets will undergo development to provide returns via organic growth or out-licensing, sale, or be spun out into new public companies.

Q BioMed is also developing a unique molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the lessening of IOP (Intraocular Pressure) - one of the chief causes of glaucoma. The platform is innovative and first-in-class. Q BioMed, together with its partner, Mannin Research, Inc, is the only company targeting this mechanism of action.

Q BioMed has commenced production of Strontium-89 Chloride. This is a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain. AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be used in combination with, or to decrease the need for opiate based drugs, and also in combination with cancer therapeutic drugs.

Q BioMed announced earlier this year an exclusive option agreement with Washington University in St. Louis. With the agreement granting the exclusive right to license the technology, the Company will evaluate the feasibility and usability of GDF-15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule now undergoing optimization for the topical treatment of glaucoma.

Recently, Q BioMed and Bio-Nucleonics announced submission of a regulatory filing to the Food and Drug Administration (FDA) for the approval of a new manufacturing facility. Upon approval by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP (Strontium-89) in accordance with cGMP.

Bio-Nucleonics is the licensor of Strontium 89 Chloride. Strontium-89 is a pure beta emitter. It selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from bone lesions.

Q BioMed, Inc. (QBIO), closed Tuesday's trading session at $1.90, up 4.40%, on 56,845 volume with 107 trades. The average volume for the last 3 months is 73,485 and the stock's 52-week low/high is $1.67/$5.90.

chart

Beleave, Inc. (BLEVF)

NetworkNewsWire, ResearchPool, 4-Traders, Midas Letter, Daily Marijuana Observer, Weed Newswire, Penny Stock Tweets, OTC Markets, New Cannabis Ventures, Equities, MarketWatch, Morningstar, Wallet Investor, The Street, InvestorsHub, Business Insider, Investing News, Cannabis Newswire, Investors Hangout, Stockhouse, Barchart, Primed Equities, TradingView, and Marketwired reported earlier on Beleave, Inc. (BLEVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Beleave, Inc. is a diversified biotechnology company with a purpose-built ACMPR licensed cannabis facility near Hamilton, Ontario. In addition, the Company has patient services clinics operating across Ontario under the Medi-Green brand. Its wholly-owned subsidiary is Beleave Kannabis Corp. Beleave’s shares trade on the OTC Markets’ OTCQX.

Beleave’s goal is to provide a consistent, reliable and standardized product to suit the requirements of every person. The Company focuses on green initiatives. It grows its plants using no pesticides. Moreover, its facilities host a large-scale, commercial, solar installation that significantly offsets its carbon footprint. Beleave’s water supply is on a closed loop system to recycle every drop.

The Company’s products include Shishkaberry, CBD god bud, and Cold Creek Kush. Shiskaberryʼs buds have a fruit and berry aroma with shades of purple. CBD god bud was created by mixing an almost pure Sativa strain called Hawaiin with a very strong purple Indica strain. Cold Creek Kush is an Indica-dominant hybrid. It crosses the strong MK Ultra and Chemdawg 91.

Beleave earlier closed on the acquisition of the Medi-Green Cannabis Clinic Network. London, Ontario is Beleave’s fourth clinic joining three Ontario locations already open in Hamilton, Kingston, and Perth.

Beleave announced in July 2018 the acquisition of 100 percent of the outstanding shares of Seven Oaks, Inc. The acquisition follows important news of Seven Oaks branded cannabis products being selected by Manitoba Liquor and Lotteries Corporation and the BC Liquor Distribution Branch for sale to consumers in deals anticipated to generate initial revenues of greater than $2,900,000. Beleave will offer Seven Oaks-branded cannabis flower, pre-rolls, as well as oils.

Earlier this month, Beleave announced that it secured genetics acquisition agreements for a wide array of cannabis seed varieties from varied lineages. There will be 90 new varieties introduced in the coming year. These have been chosen to cover the entire spectrum of low, intermediate, and high THC and CBD profiles. The list includes well-known classic Sativa and Indica varieties with applications for medical and adult recreational markets.

Beleave has developed water-soluble cannabis-infused powder and sugar products to prepare for the adult recreational cannabis-infused food and beverage market in 2019. The Company’s Hamilton, Ontario laboratory is undergoing expansion to make room for methods to formulate cannabis extracts into soluble, flavorless powders, sugar crystals, and syrups for use in beverages and food products utilizing stability-enhancing techniques for prolonged shelf-life.

Beleave’s Q2 2018 results will be released after market on Thursday, November 29, 2018 and will be followed by the Company's first ever conference call on Friday, November 30, 2018 at 11:00 a.m. (Eastern Time). The call will be hosted by Mr. Andrew T. Wnek, Chairman and Chief Executive Officer, Bojan Krasic, President and Chief Financial Officer, and select members of the Senior Management Team.

Beleave, Inc. (BLEVF), closed Tuesday's trading session at $0.09472, down 8.66%, on 246,072 volume with 60 trades. The average volume for the last 3 months is 792,101 and the stock's 52-week low/high is $0.082/$0.40.

chart

KinerjaPay Corp. (KPAY)

OTC Markets, InvestorsHub, MarketWatch, TradingView, Stockhouse, Marketbeat, and Barchart reported on KinerjaPay Corp. (KPAY), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Established in 2010, KinerjaPay Corp. focuses on operating a digital payment and e-commerce platform. The Company, through its wholly-owned subsidiary, PT Kinerja Pay Indonesia, enables consumers to "pay, play, and buy" via its secure website and mobile applications. KinerjaPay’s intention is to establish the Company as a leader in Indonesia's digital economy, with a specific emphasis on the middle- and low-income markets. KinerjaPay is based in Indonesia.

A digital payment and ecommerce platform, KinjerPay’s services are available through its mobile applications, and on its website at www.kinerjapay.com. The KinerjaPay platform provides a secure payment solution. In addition, it provides a developing virtual marketplace where participants can buy and sell products and services.

In May 2016, KinerjaPay entered into a partnership with Bitcoin Indonesia. This makes KinerjaPay the first e-commerce portal in Indonesia authorized to accept and transact Bitcoin across its platform. This enables account holders to convert the virtual currency to Indonesian Rupiah to pay their bills, transfer money, or make purchases in the Company's ecommerce market.

KinerjaPay offers several in-app services that cater to mobile users. These in-app services include an eWallet, social engagement, and digital entertainment related applications. Additionally, the Company is pursuing other e-commerce verticals. These include travel, fashion, gaming, and productivity applications.

Moreover, KinerjaPay has created a number of unique features designed to engage users. This includes an interactive gamification component that permits users to play and earn rewards while enjoying the benefits of shopping online. The Company is also providing users the convenience of making online payments of their utility bills, phone top-ups/data plans, insurance premiums, automobile loan instalments, and many other applications.

KinerjaPay plans to expand its digital ecommerce platform with the launch of KinerjaGames. It entered a long-term License Agreement with Ace Legends Pte. Ltd. (ACE). ACE is a Singapore-based game developer.

With this Agreement, in exchange for a $100,000 investment, KinerjaPay will become the exclusive, worldwide Game Publisher License for ACE games. The Company will also host all the games now published by ACE on its own KinerjaGames platform.

This past October, KinerjaPay announced its partnership with Uber Technologies, Inc. Uber is the worldwide smartphone-enabled 'Ride-Hailing' service.

With this partnership, Uber will grant KinerjaPay users an exclusive promotion code for first-time users, valid for four rides. Users can at first redeem the Uber/KinerjaPay promotion code by creating a new account on the Company's eCommerce platform or meeting a certain spending threshold with KinerjaPay's proprietary KinerjaMall service. User/clients can subsequently redeem their unique code directly in their KinerjaPay smartphone app to use the Uber service.

Last month, KinerjaPay announced that it has chosen Blockchain Industries, Inc. and Fintech Global Consultants to transition to a token payment platform. Blockchain Industries, in partnership with Fintech Global Consultants, will be guiding KinerjaPay in its transition from an electronic payment platform to a token payment platform.

KinerjaPay’s plan is to raise up to US $5 million from its imminent ICO (initial coin offerings). The ICO will be offered to institutional or private investors in the form of KCOIN, KinerjaPay's own proprietary virtual currency. With the ICO, KCOIN will be used as KinerjaPay's cryptocurrency on one of the largest cryptocurrency exchanges in Asia. 

KinerjaPay Corp. (KPAY), closed Tuesday's trading session at $0.152, up 16.92%, on 218,873 volume with 24 trades. The average volume for the last 3 months is 134,857 and the stock's 52-week low/high is $0.129/$2.83.

chart

Innovus Pharmaceuticals, Inc. (INNV)

HotTopPennyStocks, Fortune Stock Alerts, Penny Stock Bets, StockMister, 1-2-3 Stock Alerts, DSR News, Penny Stock Hub, BUYINS.NET, Promotion Stock Secrets, TopPennyStockMovers, SeeThruEquityResearch, PennyPickAlerts, PHUB News, Wall Street Mover, Penny Stock Circle, OTPicks, and StockMarketQuote reported previously on Innovus Pharmaceuticals, Inc. (INNV), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Innovus Pharmaceuticals, Inc. is a developing Over-The-Counter (OTC) consumer goods and specialty pharmaceutical business. It engages in the commercialization, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharmaceuticals is headquartered in San Diego, California.

The Company produces revenues from its lead products BTH® Testosterone Booster; BTH® Human Growth Agent; Zestra® for female arousal and EjectDelay® for premature ejaculation. It also has an additional five marketed products. These include Sensum+® for the indication of decreased penile sensitivity; Zestra Glide®; Vesele® for promoting sexual health; RecalMax™ for promoting brain and cognitive health; Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality; BTH Vision Formula; BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its Abbreviated New Drug Application (ANDA) receives approval by the FDA.

Innovus Pharmaceuticals launched AllerVarx™ in the U.S. in 2017. AllerVarx™ is a clinically proven supplement, scientifically formulated for the relief of allergy symptoms. AllerVarx™, selling in Europe under the brand name Lertal®, is a product Innovus exclusively in-licensed for the U.S. and Canada from NTC s.r.l., an Italian company.

Innovus has plans to enter the oncology supportive care OTC market with an exclusive license to two GRAS (Generally Recognized As Safe by the U.S. FDA)-listed compounds, thymol and carvacrol, for cachexia and muscle growth and repair, from the University of Iowa Research Foundation. Moreover, Innovus announced this year that the FDA cleared its GlucoGorx™ Glucose Monitoring Test Kit, which includes a glucose meter, test strips and lancet device (GlucoGorx™ Kit) under the 510(k) filing of its manufacturing partner, ACON Laboratories, Inc.

Last month, Innovus Pharmaceuticals announced that it plans to expand its product line into the hemp-derived CBD (Cannabinoid) oil-based products market starting in Q4 2018 with the introduction of MZS Sleeping Aid™. This is a supplement in tincture form delivering a 3 mg dose of melatonin per serving. It incorporates either 100 or 250 mg of hemp-derived CBD oil. The product is intended to be sold as a supplement in the United States. and eventually, pending regulatory approval, into the Canadian market.

Last week, Innovus Pharmaceuticals announced that it acquired four branded topical products from Boston Topicals, LLC, expanding its retail and e-commerce presence in the Company’s current highest revenue grossing category. The products include the diabetic retail category flagship HealthiFeet®, a foot cream.

Dr. Damaj, President and Chief Executive Officer of Innovus Pharmaceuticals, said, “We continue to bolster our product pipeline with clinically and commercially validated products that fit both our direct to consumer channels as well as retail stores.”

Innovus Pharmaceuticals, Inc. (INNV), closed Tuesday's trading session at $0.11, down 2.22%, on 335,242 volume with 45 trades. The average volume for the last 3 months is 559,092 and the stock's 52-week low/high is $0.079/$0.209.

chart

The QualityStocks Company Corner

Cyberfort Software, Inc. (CYBF)

The QualityStocks Daily Newsletter would like to spotlight Cyberfort Software, Inc. (OTC: CYBF).

The hacking of Google’s official G Suite Twitter account signals an epiphany to sophisticated tech companies that cyber security defense is an area of domain expertise. Facebook, for one, has seen the writing on the wall. After a hack compromised tens of millions of accounts on its social media portal, the company has decided to buy a cyber-security firm, according to one report (http://nnw.fm/U6bfL). Rising online threats like that are brightening the acquisition prospects of cyber-security firms and sending their valuations higher. Cyberfort Software, Inc. (OTC: CYBF) is well positioned to benefit from that increased interest, for its mission is to acquire and develop technologies that improve content filtering, ad blocking and cyber-security (http://nnw.fm/FPi3w).

Cyberfort Software, Inc. (CYBF) is a cybersecurity technology company specializing in the acquisition and development of security software, content filtering, and ad blocking technology. Headquartered in San Francisco, California, Cyberfort Software is actively dealing with various cyber threats through the development of innovative protection technologies designed for mobile, personal and business tech devices across multiple platforms.

Committed to the idea that everyone – from individuals to global corporations – should be able to enjoy a digital future free of malicious attacks robbing them of privacy and security, Cyberfort is working to strengthen its portfolio of cybersecurity IPs and stay one step ahead of cyberthreats. The growing plethora of tech devices enveloping everyday life opens the door to increasing cyberattacks through a stunning array of sophisticated cyberthreats. Protecting organizations and individuals with proactive security postures and protective measures is a key component of Cyberfort’s strategy to develop cybersecurity solutions that are smart, simple and efficient.

The company’s 2016 purchase of Vivio, a provider of pioneering AI content filtering and software protection, underscores Cyberfort’s commitment to cybersecurity. Vivio, an iOS 10 ad blocking app, currently serves over 10,000 unique users across iPhone, iPad and Mac. Vivio makes web browsing better, faster and more satisfying by blocking ads and reducing data usage, which also helps save battery life. Continuous ad blocking rule updates are delivered via an Intellectual Property Cloud-based autonomous engine with ad blocking tracker and malware detection filters.

Cyberfort recently signed a letter of intent to acquire Just Content Software which includes the Just Content app, software and underlying source code. Just Content is an efficacious and multi-functional ad blocking app that safeguards families and businesses with proprietary “Home Safe Filter” and “Business Filter” products. The Just Content app is available on iTunes and protects against unsafe links, adult content, phishing sites and inflammatory hate speech found on the internet, among other potential backdoor attacks and cyberthreats. A due diligence review is underway and a final determination regarding this acquisition is anticipated within weeks.

“Cyberfort aims to become a leader in developing cutting edge ad-blocking protective software that keeps the internet safe for families and business, which in our highly technological and immediate information-access society is a significant concern. Acquiring Just Content furthers our commitment to provide the best and most effective ad-blocking software in the marketplace,” says Cyberfort CEO Daniel Cattlin.

Favorable government regulations promoting tightened web security is a major factor driving adoption of web content filtering solution along with the public’s growing desire to better manage network bandwidth consumption and protect their online security and privacy. Cyberfort’s objective is to protect the data and integrity of personal and business computing assets and defend those assets against any threat or attack. The company’s software also offers symbiotic ad-blocking capabilities to complement its cyber defense effectiveness.

As Cyberfort continues to innovate, the Vivio team intends to leverage the current user base as a sandbox to test and optimize future incremental developments targeting an enterprise suite of tools that can be integrated into sector specific areas of growth. Key areas of focus include mobile device management, bring your own device (“BYOD”), mobile app management and secure mobile browser.

The Cyberfort leadership team is headlined by Cattlin, who offers a new age perspective to the business with expertise in project and asset management and a background in corporate finance. Cattlin brings both the operational and financial understanding to take companies from start-up and early development to expansion and capital growth within a public environment.

Chief Technology Officer Tomas Mistrik helped his team deliver a variety of technological products including the Vivio ad-blocking app for iOS 10 and the Silicon Valley-based Synergykit platform for mobile developers.

Technology Development Manager Krishna Kumar brings more than 10 years of experience in the Information Technology industry where he provided powerful security and ad-blocking measures for companies such as CSC and PayPal India.

Senior Advisor Harish Doddala brings nine years of product management and software engineering experience, delivering results for Cisco, VMware, Oracle, IBM and Siemens.

Cyberfort Software, Inc. (OTC: CYBF), closed the day's trading session at $0.45, up 25.00%, on 33,059 volume with 23 trades. The average volume for the last 3 months is 22,654 and the stock's 52-week low/high is $0.0509/$69.00.

Recent News

chart

Sharing Services, Inc. (SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services, Inc. (OTCQB: SHRV), a Texas-based diversified holdings company focused on reshaping how entrepreneurs succeed, recently had a record-breaking month, seeing $5.8 million in gross sales in August. Unlike many small companies, Sharing Services, Inc. stands out by maintaining strong financial vitality, due in large part to its burgeoning brand of health and wellness products, Elevacity Global, LLC.

Sharing Services, Inc. (SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.30, up 6.95%, on 700 volume with 2 trades. The average volume for the last 3 months is 12,747 and the stock's 52-week low/high is $0.125/$0.589.

Recent News

chart

GTX Corp (GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp (GTXO).

GPS technology-focused holding company GTX Corp (OTC: GTXO) this morning announced financial highlights for the third quarter ended September 30, 2018. According to the update, over the 2017 comparable period: third quarter financial highlights reflected an overall revenue increase of 12 percent and product sales increased 43 percent; nine month financial highlights reflected an overall revenue increase of 31 percent and product sales increase of 73 percent. To view the full press release, visit: http://nnw.fm/KH7Lv.

GTX Corp (GTXO), a For Profit For Purpose company, designs, manufactures and commercializes various products and services in the GPS tracking and monitoring business. Operating domestically and internationally, via two subsidiaries engaged in the internet of things (IoT) and wearable technology industry. Founded in 2002 and headquartered in Los Angeles, California, the company is a pioneer in Smart GPS, cellular and Bluetooth Low Energy (BLE) tracking technology, offering complete, end-to-end tracking solutions through a proprietary IoT enterprise monitoring platform – the IoT Machine to Machine platform – backed by state-of-the-art hardware, software and connectivity solutions, patents and software algorithms.

Operating under the motto “We Put the ‘Where’ in Wearable Tech,” GTX’s main goal is to keep its customers connected to who and what matters most, with each of its patented tracking technologies providing real-time location coordinates on a map via a personalized portal. The company prides itself on offering not only technologies, but also effective solutions that provide safety, security and peace of mind by helping customers locate their loved ones or lost valuable items.

With a portfolio that includes more than 80 patents filed and issued and with products and services available in 35 countries, GTX’s tracking solutions use the latest in miniaturized, low-power GPS, mobile, RF and BLE technology, that can integrate seamlessly with multiple consumer products, enterprise and military applications. The company became a U.S. Military contractor in 2017 and is already developing asset and human tracking technology for the U.S. Air Force. Its list of customers also includes public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.

The company’s flagship product is the award-winning GPS SmartSole®, the world’s first invisible wearable tracking device created specifically for people at risk of wandering, becoming lost or disoriented, including patients with Alzheimer’s, autism, dementia, traumatic brain injury and other cognitive problems. According to the World Alzheimer Report 2013 (http://nnw.fm/mrcV2), there are more than 100 million people worldwide who need constant care and monitoring because of a cognitive disorder, and their number is expected to rise to 277 million by 2050. Due to its hidden location – inside a shoe insert, the device can also be used by people undercover or at risk of kidnapping, such as government agents, military personnel, law enforcement, journalists, corporate executives, etc.

Other tracking devices designed and commercialized by the company for civilian or military use include:

  • Take-Along Tracker 3G: A powerful mini-tracking device with GPS, 2G and 3G GSM data and voice capabilities, as well as a motion sensor and sleep mode. The device can be easily attached to a keychain, lanyard, dog collar, pocket, bag or plush toy for a discreet but advanced tracking solution.
  • Invisabelt: Designed for children, this slim GPS tracker hidden inside a small waistband belt has a battery life of up to two days and is a great solution for parents who want to monitor their children’s location at all times.
  • Track My Workforce: An easy and cost-effective solution that allows businesses to track and monitor their mobile workforce. The app is available for both Android and iOS systems, and allows employers to monitor their workforce from a single company account.
  • P.E.T.S. -Personnel Equipment Tracking System: Currently in use at the Edwards Air Force Base, this tracking system allows real-time monitoring and surveillance of personnel and assets and has a 200+ square mile coverage. Solar powering capabilities and extend battery life allow the tracker to be used in areas without existing power sources.
  • GPS Rifle Tracker: The company’s smallest GPS tracker, designed to withstand shocks and water submersion due to its robust, military standard enclosure, can be mounted on any AR15 platform picatinny rail to detect weapon discharge, track weapons and inventory, and send time and location alerts.

Led by a management team with solid experience in wearable technology, IoT, consumer electronics, mobile and technology licensing, as well as finance and the footwear industry, GTX plans to leverage its core technology platform to reach new verticals via licensing agreements and strategic partnerships, and to monetize its intellectual property portfolio. The monetization campaign kicked off in 2017 has already identified 100 companies that could become licensees. Besides military and law enforcement, the company also eyes the biometrics market, home health, medicare and insurance and other security applications for potential uses of its IoT platform and tracking technology.

GTX currently has 15 domestic and international distributors, subscribers in 35 countries and more than 700 online affiliates. With multiple revenue streams, several consecutive years of double-digit revenue growth and a strong pipeline of lucrative commercial products, GTX is uniquely positioned to become a leading provider of tracking solutions on this growing multi-billion-dollar market.

GTX Corp (GTXO), closed the day's trading session at $0.0135, up 8.87%, on 296,872 volume with 20 trades. The average volume for the last 3 months is 154,622 and the stock's 52-week low/high is $0.006/$0.4494414.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

The rapid growth of the cannabis sector is pushing companies to innovate expansion strategies. Hydroponics supplier Sugarmade, Inc. (OTCQB: SGMD) has leaned into the current trend for mergers, with a big acquisition and open plans for future growth.

Sugarmade, Inc. (SGMD) one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.10, up 0.10%, on 1,126,485 volume with 132 trades. The average volume for the last 3 months is 2,366,121 and the stock's 52-week low/high is $0.05/$0.43.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (MCOA) and its joint venture partner Global Hemp Group (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) are pleased to provide an update on the harvest at their high yielding CBD hemp project in Scio, Oregon. Also today, the company was highlighted in a report explaining that, while there may have been a recent pull back on Cannabis stocks, grow operations show no signs of slowing and instead continue to expand. Additionally, the company was featured today in a report by CannabisNewsWire which examines how recent changes in Washington, D.C., are good news for the U.S. hemp industry.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.01815, up 0.83%, on 6,233,871 volume with 271 trades. The average volume for the last 3 months is 9,562,514 and the stock's 52-week low/high is $0.0165/$0.0728.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was highlighted today in an article examining how, while there may have been a recent pull back on Cannabis stocks, grow operations show no signs of slowing and instead continue to expand.  The cannabis industry’s growth is forcing cannabis companies to evaluate the current state of their operations, both in terms of scale and efficiency.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $2.38825, up 1.67%, on 407,749 volume with 753 trades. The average volume for the last 3 months is 1,545,929 and the stock's 52-week low/high is $1.87/$7.894.

Recent News

chart

NUGL Inc. (NUGL)

The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL Inc. (OTC: NUGL) (the “Company”), the cannabis industry's new standard of technology, is pleased to announce a full-scale marketing launch into the cannabis industry from all NUGL platforms and publications.

NUGL Inc. (NUGL) is focused on leading the evolution in business relations, development and organic data in the cannabis industry with a distinct platform. In this effort, it has developed a leading-edge, first of its kind search app and online directory for the marijuana industry that provides a one-stop source and listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $2.04, up 1.24%, on 113,651 volume with 156 trades. The average volume for the last 3 months is 182,101 and the stock's 52-week low/high is $0.405/$2.64.

Recent News

chart

CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that Nader Pourhassan, Ph.D., President and Chief Executive Officer and Richard Pestell, M.D., Ph.D., F.A.C.P., M.B.A., Chief Medical Officer, will present at the following investment conferences

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.595375, off by 3.66%, on 42,785 volume with 23 trades. The average volume for the last 3 months is 226,878 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was highlighted today in an article examining how, in the U.S., people who admit using or test positive for cannabis are routinely denied kidney transplants or turned away when they offer to donate their kidneys. This practice has gone unchallenged until a recent study proved that marijuana doesn’t affect the outcomes of kidney transplant surgery.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.6919, off by 5.89%, on 382,836 volume with 188 trades. The average volume for the last 3 months is 494,369 and the stock's 52-week low/high is $0.682/$3.29.

Recent News

chart

DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

DPW Holdings, Inc. (NYSE American: DPW), a diversified holding company, announced today that its Board of Directors, at a meeting on Friday, November 23, 2018, has authorized the officers of DPW to pursue a spinoff of DPW’s wholly-owned subsidiary Super Crypto Mining, Inc. (“Super Crypto”).

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

  • The highest efficiency and highest density power converters and inverters
  • Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
  • Very high-frequency filters
  • Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

  • Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
  • Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
  • Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
  • Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
  • Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

  • Achieve compounded annual revenue growth of 25-35%
  • Achieve compounded annual net Income growth of 5%
  • Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.2285, off by 3.30%, on 1,635,768 volume with 2,532 trades. The average volume for the last 3 months is 1,238,073 and the stock's 52-week low/high is $0.219/$5.95.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint (OTCQB:SING) a fully reporting technology company providing mobile payments, ancillary cannabis services and blockchain solutions announces that it has entered into an agreement with TorusMed Inc., a subsidiary of PetroSun Inc. (OTCPINK:PSUD) to distribute TorusMed Hemp CBD products on two of their e-commerce channels; SingleSeed.com and DIGSHydro.com. TorusMed will drop ship product directly to the customers.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.01982, even for the day, on 1,475,545 volume with 91 trades. The average volume for the last 3 months is 4,518,130 and the stock's 52-week low/high is $0.0178/$0.133.

Recent News

chart

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Medical Cannabis Payment Solutions (OTC: REFG) provides payment and management solutions to the legal cannabis industry. The company serves this industry with a premier end-to end payment processing system. This proprietary payment system is called “Go.” A FinCEN (Financial Crimes Enforcement Network) compliant enterprise, Medical Cannabis Payment Solutions has its corporate office in Cheyenne, Wyoming.

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.0214, off by 1.15%, on 106,500 volume with 18 trades. The average volume for the last 3 months is 464,764 and the stock's 52-week low/high is $0.0165/$0.092.

Recent News

chart

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CHMJF).

Chemistree Technology Inc. (CSE:CHM, OTCQB:CHMJF, FRA: CM1) (the “Company” or “Chemistree”) is pleased to announce that the Company has entered into a strategic collaboration (the “Collaboration”) with a Humboldt County-based cannabis processing company (the “Processor”) located in Arcata, California. Pursuant to the Collaboration, Chemistree will loan the Processor US$450,000 (the “Loan”), and the parties also intend to negotiate an additional line of credit for working capital purposes.

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF) an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements’ expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company “maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S.”

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree’s working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed the day's trading session at $0.34, even for the day, on 49,218 volume with 49 trades. The average volume for the last 3 months is 2,270 and the stock's 52-week low/high is $0.268/$0.7158.

Recent News

chart

American Premium Water Corp. (HIPH)

The QualityStocks Daily Newsletter would like to spotlight American Premium Water Corp. (HIPH).

American Premium Water Corp. (HIPH), headquartered in Playa Vista, California, is a diversified holding company, manufacturer, distributor and marketer of branded consumer products. HIPH, the acronym for “Hi-Power of Hydro,” maintains a portfolio of subsidiaries catering to the health-conscious consumer and luxury fashion brand connoisseur. The company’s two main pillars focus on the development of health and beauty biotech, dedicated to unlocking the power of hydrogen and nanotechnologies. Paired with cannabidiol or “CBD” in a unique beverage, the technology is proving to be a significant health and wellness option for astute consumers.

Among the company’s holdings are:

  • LALPINA Hydro beverages mix hydrogen with nanotechnology into consumer beverages that combine the best of health, nutrition and fitness to deliver short and long-term therapeutic health benefits. LALPINA Hydro utilizes atomic molecular hydrogen, or diatomic hydrogen, which converts antioxidants in the body to H2O to further enhance hydration, which helps increase endurance, reduce lactic acid and melt away fatigue. Over 500 peer-reviewed articles demonstrate hydrogen to have therapeutic potential in essentially every organ of the human body and in 150 different human disease models.
  • LALPINA Hydro CBD is a technically superior CBD-infused beverage. Using hydro and nanotechnology, LALPINA Hydro CBD encapsulates water molecules with cannabidiol molecules, making them infinitely more bioavailable and accelerating delivery to the body’s cells and tissues. Each bottle of LALPINA Hydro CBD contains 3 million nanograms of CBD free from the psychoactive compound THC (tetrahydrocannabinol). HIPH is the first to introduce a hydro-nano CBD-infused beverage on the market, which is a more effective delivery mechanism for administering CBD into the blood stream than traditional beverages or oils, with up to a 90 percent higher absorption rates.

The company recently signed a distribution agreement for its subsidiary, LALPINA Hydro CBD, to sell its beverages to two SinglePoint, Inc. (OTCQB: SING) e-commerce channels: SingleSeed.com and DIGSHydro.com. SING is a technology and investment company with a portfolio that includes mobile payments, blockchain solutions and ancillary cannabis services. HIPH will drop ship its product to the customers.

HIPH CEO Ryan Fishoff said the e-commerce arrangements “could bring in excess of a million of revenue over the life of the agreement.” The agreement serves as a pillar of the company’s e-commerce distribution strategy, driving awareness and impressions for the LALPINA brand.

In addition, HIPH seeks to market emerging fashion brands and leverage its relationship with classic retail partners while incorporating disruptive blockchain technologies to expand its retail footprint with the following:

  • Gents, a producer of luxury hats and other fine accessories and apparel, was acquired in September 2017. Gents is distributed across many luxury retail outlets including Saks Fifth Avenue, Bloomingdales, Nordstrom, and other high-end channels. The company added the Worthy streetwear brand to its portfolio in June 2018.
  • HIPH also acquired the license to operate the FashionCoinX exchange, a blockchain exchange focused on creating utility tokens for the fashion industry, and created THRD Coin, a multi-branded utility rewards token that is also the first token to be traded on the exchange. The company is leveraging its retail footprint and expertise in the fashion and apparel space with the burgeoning blockchain sector.

American Premium Water Corp. (HIPH), closed the day's trading session at $0.0385, off by 3.27%, on 5,396,651 volume with 264 trades. The average volume for the last 3 months is 18,336,829 and the stock's 52-week low/high is $0.0035/$0.1319.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.